PE65998A1 - SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS - Google Patents

SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS

Info

Publication number
PE65998A1
PE65998A1 PE1997000362A PE00036297A PE65998A1 PE 65998 A1 PE65998 A1 PE 65998A1 PE 1997000362 A PE1997000362 A PE 1997000362A PE 00036297 A PE00036297 A PE 00036297A PE 65998 A1 PE65998 A1 PE 65998A1
Authority
PE
Peru
Prior art keywords
preference
alkyl
substituted
oxybutyric
acids
Prior art date
Application number
PE1997000362A
Other languages
Spanish (es)
Inventor
Jinshan Chen
David R Brittelli
Brian R Dixon
Zandt Michael C Van
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE65998A1 publication Critical patent/PE65998A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA GENERAL "A-D-E-G", EN DONDE: "A" ES ALQUILO C9-C14 O ALQUILOXI C9-C18, ENTRE OTROS; "D" ES DE PREFERENCIA CO; "E" ES UNA CADENA DE n ATOMOS DE CARBONO QUE LLEVAN m SUSTITUYENTES R6, EN DONDE n ES 2 o 3; m ES 1; 2 o 3; R6 ES ALQUILO C1-C10 O -(CH2)t-R7, ENTRE OTROS; t ES 0; 1; 2; 3; 4; 5 o 6; R7 ES DE PREFERENCIA ISOINDOL 1,3 DIONA, ENTRE OTROS; "G" ES DE PREFERENCIA COOH; SIENDO EL COMPUESTO PREFERIDO EL DE FORMULA (I) EN DONDE: R15 ES H; Z ES DE PREFERENCIA (CH2)7; Y ES 0; 2 o 3; R16 ES ETILFENIL O FTALIMIDIL SUSTITUIDOS POR (R4)x, EN DONDE R4 ES HALURO, ALQUILO C1-C6 o OR, ENTRE OTROS; R ES H O ALQUILO C1-C6; x ES 0; 1; 2; 3 o 4. ESTOS COMPUESTOS ACTUAN COMO INHIBIDORES DE LAS METALOPROTEASAS DE LA MATRIZ (MMP) QUE POSEEN MEJOR BIODISPONIBILIDAD Y ESTABILIDAD BIOLOGICA, SIENDO UTILES PARA: (a) MITIGAR LOS EFECTOS DE LA OSTEOARTRITIS O ARTRITIS REUMATOIDEA, ENTRE OTROS; (b) RETARDAR LA METASTASIS DE TUMORES O LA PERDIDA DEGENERATIVA DE CARTILAGO POSTERIOR A UNA LESION ARTICULAR TRAUMATICA; (c) REDUCIR LA TROMBOSIS; O (d) PRACTICAR EL CONTROL DE LA NATALIDADTHEY REFER TO COMPOUNDS OF GENERAL FORMULA "A-D-E-G", WHERE: "A" IS ALKYL C9-C14 OR ALKYLOXI C9-C18, AMONG OTHERS; "D" IS OF PREFERENCE CO; "E" IS A CHAIN OF n CARBON ATOMS CARRYING m R6 SUBSTITUTES, WHERE n IS 2 or 3; m IS 1; 2 or 3; R6 IS C1-C10 ALKYL O - (CH2) t-R7, AMONG OTHERS; t IS 0; one; two; 3; 4; 5 or 6; R7 IS OF PREFERENCE ISOINDOL 1,3 DIONA, AMONG OTHERS; "G" IS OF PREFERENCE COOH; THE PREFERRED COMPOUND BEING THE FORMULA (I) WHERE: R15 IS H; Z IS OF PREFERENCE (CH2) 7; Y IS 0; 2 or 3; R16 IS ETHYLPHENYL OR FTALIMIDIL SUBSTITUTED BY (R4) x, WHERE R4 IS HALIDE, C1-C6-ALKYL or OR, AMONG OTHERS; R IS H O C1-C6 ALKYL; x IS 0; one; two; 3 or 4. THESE COMPOUNDS ACT AS INHIBITORS OF MATRIX METALOPROTEASES (MMP) THAT HAVE BETTER BIODAVAILABILITY AND BIOLOGICAL STABILITY, BEING USEFUL TO: (a) MITIGATE THE EFFECTS OF OSTEOARTHRITIS OR RHEUMATROID ARTHRITIS; (b) DELAYING THE METASTASIS OF TUMORS OR THE DEGENERATIVE LOSS OF CARTILAGE AFTER A TRAUMATIC ARTICULAR INJURY; (c) REDUCE THROMBOSIS; OR (d) PRACTICE BIRTH CONTROL

PE1997000362A 1996-05-15 1997-05-12 SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS PE65998A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
PE65998A1 true PE65998A1 (en) 1998-10-20

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000362A PE65998A1 (en) 1996-05-15 1997-05-12 SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS

Country Status (18)

Country Link
EP (1) EP0912487A1 (en)
JP (1) JP3417951B2 (en)
CN (1) CN1163466C (en)
AR (1) AR007096A1 (en)
AU (1) AU727648B2 (en)
CA (1) CA2253869C (en)
CO (1) CO4990925A1 (en)
HR (1) HRP970246B1 (en)
ID (1) ID20291A (en)
MY (1) MY132470A (en)
PA (1) PA8429401A1 (en)
PE (1) PE65998A1 (en)
SV (1) SV1997000034A (en)
TN (1) TNSN97085A1 (en)
TW (1) TW467892B (en)
WO (1) WO1997043238A1 (en)
YU (1) YU18797A (en)
ZA (1) ZA974032B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
US20100324081A1 (en) * 2007-08-15 2010-12-23 Kyorin Pharmaceutical Co., Ltd. Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
EP3126339A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
JP2017509665A (en) 2014-04-03 2017-04-06 バイエル ファーマ アクチエンゲゼルシャフト 2,5-Disubstituted cyclopentanecarboxylic acids for the treatment of airway diseases
JP2017511319A (en) 2014-04-03 2017-04-20 バイエル ファーマ アクチエンゲゼルシャフト Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69529100T2 (en) * 1994-01-22 2003-07-17 British Biotech Pharm metalloproteinase

Also Published As

Publication number Publication date
CA2253869C (en) 2003-04-22
ID20291A (en) 1998-11-19
TW467892B (en) 2001-12-11
TNSN97085A1 (en) 2005-03-15
YU18797A (en) 1999-11-22
PA8429401A1 (en) 2000-05-24
HRP970246B1 (en) 2002-04-30
WO1997043238A1 (en) 1997-11-20
JP3417951B2 (en) 2003-06-16
CN1225622A (en) 1999-08-11
ZA974032B (en) 1998-02-19
JPH11509870A (en) 1999-08-31
CO4990925A1 (en) 2000-12-26
MY132470A (en) 2007-10-31
AR007096A1 (en) 1999-10-13
CN1163466C (en) 2004-08-25
EP0912487A1 (en) 1999-05-06
AU727648B2 (en) 2000-12-21
SV1997000034A (en) 1999-07-05
CA2253869A1 (en) 1997-11-20
HRP970246A2 (en) 1998-04-30
AU3121997A (en) 1997-12-05

Similar Documents

Publication Publication Date Title
FI955438A0 (en) N-acylsulphamic acid esters (or thioesters), N-acylsulphonamides and N-sulphonylcarbamic acid esters (or thioesters) as hypercholesterolemic substances
BRPI9915679A8 (en) COMPOSITIONS AND METHODS TO INCREASE BONE MINERALIZATION
ES2015950B3 (en) COLLAGEN COMPOSITIONS FOR ARRANGING BONES CONTAINING AUTOGENIC MEDULA.
FI971312A0 (en) New prostagladin synthase inhibitors
ATE239445T1 (en) COSMETIC COMPOSITION CONTAINING HYDROPHOBIC STARCH DERIVATIVES
ES2036190T3 (en) NEW DERIVATIVES OF DIPHOSPHONIC ACIDS, PROCEDURE FOR THE PREPARATION AND MEDICINES CONTAINED IN THESE COMPOUNDS.
MX9305077A (en) POLYMERIC AMMONIUM SALTS, RETICULATED AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM.
ES554688A0 (en) PROCEDURE FOR OBTAINING ESTERS OF ACID (MET) -ACRYLIC
PE65998A1 (en) SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS
PE66898A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED BIARILOXOBUTIRIC ACIDS
MX16572A (en) PROCEDURE FOR THE PREPARATION OF NEW SUBSTITUTED SULFONAMIDES PRODUCT OBTAINED AND PHARMACEUTICAL COMPOSITIONS INCLUDING IT.
ES2136888T3 (en) INHIBITORS FOR THE PROLIFERATION OF SMOOTH MUSCLE CELLS.
DE69902127T2 (en) HISTONE CONTAINING COMPOSITION FOR TREATING RHEUMATIC ARTHRITIS
DE69510338D1 (en) AZIRDINE DERIVATIVES, THEIR PRODUCTION AND USE
ES2158083T3 (en) STABILIZING MIXTURE CONSTITUTED BY CHROME DERIVATIVES, PHOSPHITES OR ORGANIC AND AMINAS PHOSPHONITES.
PE66298A1 (en) INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED PHENETHYLENE COMPOUNDS
ATE244565T1 (en) USE OF 2-ARYL-3-AROYLBENZO(B)THIOPHENE TO TREAT ESTROGEN ABSTENTION SYNDROME
ES2109103T3 (en) PROCEDURE FOR THE PREPARATION OF TRIALQUILSILIL-7 BACATINA III.
IT1275997B1 (en) ENAMINES AS VULCANIZATION ACCELERANTS FOR NATURAL OR SYNTHETIC RUBBERS
ES2125348T3 (en) A PROCEDURE FOR PREPARING A STABLE CRYSTALLINE SODIUM PERCARBONATE.
PT95990A (en) METHOD FOR THE PREPARATION OF NEW THIOFEN DERIVATIVES
DE69329199D1 (en) SULFUR-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM
FI963168A0 (en) New Indan-2-Mercaptoacetylamide Disulfide Derivatives Useful as Enkephalinase Inhibitors
PE2099A1 (en) HYDROXAMIC ACID DERIVATIVES
BR9911585A (en) Compounds derived from an alpha-d-xylose, method for preparation and therapeutic use

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed